Calciphylaxis: Controversies in pathogenesis, diagnosis and treatment

American Journal of the Medical Sciences

Volumn 351, Issue 2, 2016, Pages 217-227

  Jeong, Haneol S ^a   Dominguez, Arturo R ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Calcific uremic arteriolopathy; Calciphylaxis; Diagnosis; Pathogenesis; Treatment

Indexed keywords

ANALGESIC AGENT; ANTICOAGULANT AGENT; CALCIUM; PHOSPHORUS; SODIUM THIOSULFATE;

ANALGESIA; ANTICOAGULANT THERAPY; ARTICLE; BIOPSY; CALCINOSIS; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COMORBIDITY; DIFFERENTIAL DIAGNOSIS; EMERGENCY CARE; HUMAN; KIDNEY TRANSPLANTATION; LABORATORY TEST; LONG TERM CARE; MEDICAL HISTORY; NURSING CARE; NURSING HOME; PATHOGENESIS; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; RISK FACTOR; TERMINAL CARE; WOUND CARE; ANIMAL; CALCIPHYLAXIS; CHRONIC KIDNEY FAILURE; COMPLICATION; RAT;

ANIMALS; CALCIPHYLAXIS; HUMANS; KIDNEY FAILURE, CHRONIC; RATS; RISK FACTORS;

EID: 84960886427     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1016/j.amjms.2015.11.015     Document Type: Article

References (69)

1. Coates T, Kirkland GS, Dymock RB, et al. Cutaneous necrosis from calcific uremic arteriolopathy. Am J Kidney Dis 1998;32:384-91.
2. Mochel MC, Arakari RY, Wang G, et al. Cutaneous calciphylaxis: a retrospective histopathologic evaluation. Am J Dermatopathol 2013;35(5): 582-586.
3. Zembowicz A, Navarro P, Walters S, et al. Subcutaneous thrombotic vasculopathy syndrome: an ominous condition reminiscent of calciphy-laxis: calciphylaxis sine calcifications? Am J Dermatopathol 2011;33(8): 796-802.
4. Hafner J, Keusch G, Wahl C, et al. Uremic small-artery disease with medial calcification and intimal hyperplasia (so-called calciphylaxis): a complication of chronic renal failure and benefit from parathyroidectomy. J Am Acad Dermatol 1995;33:954-62.
5. Rogers NM, Teubner DJO, Coates PTH. Calcific uremic arteriolopathy: advances in pathogenesis and treatment. Semin Dial 2007;20(2):150-7.
6. Handa S, Strzelczak D. Uremic small artery disease: calciphylaxis with penis involvement. Clin Nephrol 1998;50:258-61.
7. Barbera V, Di Lullo L, Gorini A, et al. Penile calciphylaxis in end stage renal disease. Case Rep Urol 2013;968916.
8. Kazanji N, Falatko J, Neupane S, et al. Calciphylaxis presenting as digital ischemia. Intern Emerg Med 2015;10(4):529-30.
9. Maclean C, Brahn E. Systemic lupus erythematosus: calciphylaxis induced cardiomyopathy. J Rheumatol 1995;22:177-9.
10. Matsuo T, Tsukamoto Y, Tamura M, et al. Acute respiratoryfailure due to pulmonary calciphylaxis in a maintenance haemodialysis patient. Nephron 2001;87:75-9.
11. Klassen-Broekema N, van Bijsterveld O. A local challenger of ocular calciphylaxis in patients with chronic renal failure: a hypothesis. Graefes Arch Clin Exp Ophthalmol 1995;233:717-20.
12. Rogers NM, Coates PTH. Calcific uraemic arteriolopathy: an update. Curr Opin Nephrol Hypertens 2008;17(6):629-34.
13. Fine A, Fontaine B. Calciphylaxis: the beginning of the end? Perit Dial Int 2008;28(3):268-70.
14. Nigwekar Su, Solid CA, Ankers E, et al. Quantifying a rare disease in administrative data: the example of calciphylaxis. J Gen Intern Med 2014; 29(suppl 3):S724-31.
15. Pollock B, Cunliffe W, Merchant W. Calciphylaxis in the absence of renal failure. Clin Exp Dermatol 2000;25:389.
16. Goyal S, Huhn K, Provost T. Calciphylaxis in a patient without renal failure or elevated parathyroid hormone: the possible aetiological role of chemotherapy. Br J Dermatol 2000;143:1087.
17. Fine A, Zacharias J. Calciphylaxis is usually nonulcerating: risk factors, outcome and therapy. Kidney Int 2002;61:2210-7.
18. Mazhar AR, Johnson RJ, Gillen D, et al. Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int 2001;60:324-32.
19. Weenig R, Sewell L, Davis M, et al. Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol 2007;56:569-79.
20. Bleyer AJ, Choi M, Igwemezie B, et al. A case control study of proximal calciphylaxis. Am J Kidney Dis 1998;32:376-83.
21. Ahmed S, O'Neill KD, Hood AF, et al. Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells. Am J Kidney Dis 2001;37:267-76.
22. Brandenburg VM, Cozzolino M, Ketteler M. Calciphylaxis: a still unmet challenge. J Nephrol 2011;24(2):142-8.
23. Selye H, Gentile G, Prioreschi P. Cutaneous molt induced by calciphylaxis in the rat. Science 1961;134:1876-7.
24. Lin WT, Chao CM. Tumoral calcinosis in renal failure. Q J Med 2014; 107(5):387.
25. Block G. Control of serum phosphorus: implications for coronary artery calcification and calcific uremic arteriolopathy (calciphylaxis). Curr Opin Nephrol Hypertens 2001;10:741-7.
26. Reynolds J, Joannides A, Skepper J, et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004;15:2857-67.
27. Shanahan CM, Crouthamel MH, Kapustin A, et al. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res 2011;109(6):697-711.
28. Moe SM, Chen NX. Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol 2008;19(2):213-6.
29. Sowers KM, Hayden MR. Calcific uremic arteriolopathy: pathophysiology, reactive oxygen species, and therapeutic approaches. Oxid Med Cell Longev 2010;3(2):109-21.
30. Griethe W, Schmitt R, Jurgensen JS, et al. Bone morphogenic protein-4 expression in vascular lesions of calciphylaxis. J Nephrol 2003; 16(5):728-32.
31. Feng JQ, Xing L, Zhang JH, et al. NFKappaB specifically activates BMP-2 gene expression in growth plate chondrocytes in vivo and in a chondrocytes cell line in vitro. J Biol Chem 2003;278(31):29130-5.
32. Nigwekar SU, Wolf M, Stems RH, et al. Calciphylaxis from non-uremic causes: a systemic review. Clin J Am Soc Nephrol 2008;3(11):39-43.
33. Saghazadeh A, Hafizi S, Rezaei N. Inflammation in venous thromboembolism: cause or consequence? Int Immunopharmacol 2015;28(1): 655-65.
34. Edelstein CL, Wickham MK, Kirby PA. Systemic calciphylaxis presenting as a painful, proximal myopathy. Postgrad Med J 1992;68(797): 209-11.
35. Katsamakis G, Lukovits TG, Gorelick PB. Calcific cerebral embolism in systemic calciphylaxis. Neurology 1998;51(1):295-7.
36. Yerram P, Chaudhary K. Calcific uremic arteriolopathy in end stage renal disease: pathophysiology and management. Ochsner J 2014;14(3): 380-5.
37. Zacharias JM, Fontaine B, Fine A. Calcium use increases risk of calciphylaxis: a case-control study. Perit Dial Int 1999;19(3):248-52.
38. Ruggian JC, Maesaka JK, Fiashbane S. Proximal calciphylaxis in four insulin-requiring diabetic hemodialys is-patients. Am J Ki dney Dis 1996; 28(3):409-14.
39. Galloway PA, El-Damanawi R, Bardsley V. Vitamin K antagonists predispose to calciphylaxis in patients with end-stage renal disease. Nephron 2015;129(3):197-201.
40. Hayashi M, Takamatsu I, Kanno Y, et al. A case-control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol Dial Transplant 2012;27(4):1580-4.
41. Price PA, Faus SA, Williamson MK. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol 1998;18(9):1400-7.
42. Fusaro M, Noale M, Vila V, et al. Vitamin K, vertebral fractures, vascular calcifications, and mortal ity: Vitamin K Italian (VIKI) dialysis study. J Bone Miner Res 2012;27(11):2271-8.
43. Lee JL, Naguwa SM, Cheema G, et al. Recognizing calcific uremic arteriolopathy in autoimmune disease: an emerging mimicker of vasculitis. Autoimmun Rev 2008;7(8):638-43.
44. Nazarian RM, Van Cott EM, Zembowicz A, et al. Warfarin-induced skin necrosis. J Am Acad Dermatol 2009;61(2):325-32.
45. Essex DW, Wynn SS, Jin DK. Late-onset warfarin-induced skin necrosis: case report and review of the literature. Am J Hematol 1998; 57(3):233-7.
46. Shmidt E, Murthy NS, Knudsen JM, et al. Net-like pattern of calcification on plain soft-tissue radiographs in patients with calci phylaxis. J Am Acad Dermatol 2012;67(6):1296-301.
47. Han MM, Pang J, Shinkai K, et al. Calciphylaxis and bone scintigraphy: case report with histological confirmation and review of the literature. Ann Nucl Med 2007;21(4):235-8.
48. Sandhu G, Gini MB, Ranade A, et al. Penile calciphylaxis: a life-threatening condition successfully treated with sodium thiosulfate. Am J Ther 2012;19(1):e66-8.
49. Fonder MA, Lazarus GS, Cowan DA, et al. Treating the chronic wound: a practical approach to the care of nonhealing wounds and wound care dressings. J Am Acad Dermatol 2008;58(2):185-206.
50. An J, Devaney B, Ooi KY, et al. Hyperbaic oxygen in the treatment of calciphylaxis: a case series and literature review. Nephrology (Carlton) 2015;20(7):444-50.
51. Tittelbach J, Graefe T, Wollina U. Painful ulcers in calciphylaxis-combined treatment with maggot therapy and oral pentoxyfillin. J Dermatolog Treat 2001;12(4):211-4.
52. Lai G, Nowell AG, Liao J, et al. Determinants of survival in patients with calciphylaxis: a multivariate analysis. Surgery 2009;146(6):1028-34.
53. Strazzula L, Nigwekar SU, Steele D, et al. Intralesional sodium thiosulfate for the treatment of calciphylaxis. JAMA Dermatol 2013;149(8): 946-9.
54. Garcia CP, Roson E, Peon G, et al. Calciphylaxis treated with sodium thiosulfate: report of two cases. Dermatol Online J 2013;19(9):19616.
55. Selk N, Rodby RA. Unexpectedly severe metabolic acidosis associated with sodium thiosulfate therapy in a patient with calcificuremic arteri ol-opathy. Semin Dial 2011;24(1):85-8.
56. Schlieper G, Brandenburg V, Ketteler M, et al. Sodium thiosulfate in the treatment of calcific uremic arteriolopathy. Nat Rev Nephrol 2009;5(9): 539-43.
57. Al Bugami MM, Wilson JA, Clarke JR, et al. Oral sodium thiosulfate as maintenance therapy for calcific uremic arteriolopathy: a case series. Am J Nephrol 2013;37(2):104-9.
58. Rosenbaum DP, Mandeville WH, Pitruzzello M, et al. Effects of Rena Gel, a non-absorbable, cross-linked, polymeric phosphate binder, on urinary phosphorus excretion in rats. Nephrol Dial Transplant 1997;12(5): 9611-964.
59. Garg JP, Chasan-Taber S, Blair A, et al. Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial. Arthritis Rheum 2005;52(1):290-5.
60. Floege J, Kubo Y, Floege A, et al. The effect of cinacalcet on calcific uremic arteriolopathy events in patients receivi ng hemod ialysis: the EVOLVE trial. Clin J Am Soc Nephrol 2015;10(5):800-7.
61. Kane WJ, Petty PM, Sterioff S, et al. The uremic gangrene syndrome: improved healing in spontaneously forming wounds following subtotal parathyroidectomy. Plast Reconstr Surg 1996;98(4):671-8.
62. Deree J, Martins JO, Melbostad H, et al. Insights into the regulation of TNF-alpha production in human mononuclear cells: the effects of nonspecific phosphodiesterase inhibition. Clinics (Sao Paolo) 2008;63(3):321-8.
63. Marques LJ, Zheng L, Poulakis N, et al. Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages. Am J Respir Crit Care Med 1999;159(2):508-11.
64. Ward A, Clissold SP. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficiency. Drugs 1987;34(1):50-97.
65. Full R, Delmore T, Carter C, et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 1992;306(4):189-94.
66. Pautas E, Gouin I, Bellot O, et al. Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients. Drug Saf 2002;25(10):725-33.
67. Caluwe R, Vandecasteele S, Van Vlem B, et al. Vitamin K2 supplementation in haemodialysis patients: a randomized dose-finding study. Nephrol Dial Transplant 2014;29(7):1385-90.
68. Bhat S, Hedge S, Bellovich K, et al. Complete resolution of calciphylaxis after kidney transplantation. Am J Kidney Dis 2013;62(1): 132-4.
69. Vanbelleghem H, Terryn W, Van leuven L, et al. A dramatic case of calciphylaxis 20 years after kidney transplantation. Nephrol Dial Transplant 2004;19(12):3183-5.